- Market Capitalization, $K 52,493
- Shares Outstanding, K 47,291
- Annual Sales, $ 15,090 K
- Annual Income, $ -39,010 K
- 60-Month Beta 1.36
- Price/Sales 3.64
- Price/Cash Flow N/A
- Price/Book 1.51
|Period||Period Low||Period High||Performance|
| || |
-0.17 (-13.28%)since 06/21/19
| || |
-0.78 (-41.27%)since 04/23/19
| || |
-2.82 (-71.72%)since 07/23/18
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that Adamis and kaleo Inc. agreed to settle all previously announced litigation between the parties, including the case filed...
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) provided an update that Sandoz Inc. (Sandoz), a Novartis division, today announced the U.S. retail launch of SYMJEPI(TM) (epinephrine) 0.3 mg and 0.15...
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the litigation with kaleo Inc. regarding kaleo's claims of patent infringement relating to Adamis' higher dose naloxone injection...
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proposed brand name for the company's high dose naloxone product...
Adamis (ADMP) delivered earnings and revenue surprises of -11.76% and -17.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO (AP) _ Adamis Pharmaceuticals Corp. (ADMP) on Thursday reported a loss of $8.9 million in its first quarter.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis"), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory...
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GrafTech International Ltd....
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update.
The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.
Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.
The market is approaching oversold territory. Be watchful of a trend reversal.